Obesity and type 2 diabetes: Which patients are at risk?

Diabetes, Obesity and Metabolism

Volumn 14, Issue 5, 2012, Pages 399-408

  Garber, A J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Diabetes complications; Glucose metabolism; Insulin resistance; Treatment guidelines; Type 2 diabetes; Weight loss therapy

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; EXENDIN 4; LIRAGLUTIDE; LORCASERIN; METFORMIN; PHENTERMINE PLUS TOPIRAMATE; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

AMNESIA; ANXIETY; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DEPRESSION; DISEASE COURSE; EATING HABIT; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET CELL FUNCTION; PATIENT IDENTIFICATION; PHYSICAL ACTIVITY; REVIEW; SIDE EFFECT; WEIGHT REDUCTION;

EID: 84859441376     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01536.x     Document Type: Review

References (107)

1. Sherry B, Blanck HM, Galuska DA, Pan L, Dietz WH, Balluz L. Centers for Disease Control and Prevention. Vital signs: state-specific obesity prevalence among adults-United States, 2009. MMWR Morb Mortal Wkly Rep 2010; 59: 951-955.
2. The United States of Diabetes: Challenges and opportunities in the decade ahead. 2010. Available from URL:. Accessed 11 November 2011.
3. Garber AJ, Handelsman Y, Einhorn D et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract 2008; 14: 933-946.
4. Puhl RM, Heuer CA. Obesity stigma: important considerations for public health. Am J Public Health 2010; 100: 1019-1028.
5. Teixeira ME, Budd GM. Obesity stigma: a newly recognized barrier to comprehensive and effective type 2 diabetes management. J Am Acad Nurse Pract 2010; 22: 527-533.
6. Linde JA, Jeffery RW, Levy RL et al. Binge eating disorder, weight control self-efficacy, and depression in overweight men and women. Int J Obes Relat Metab Disord 2004; 28: 418-425.
7. Danaei G, Ding EL, Mozaffarian D et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med 2009; 6: e1000058.
8. Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res 2001; 9(Suppl. 4): 326S-334S.
9. Bays HE, Chapman RH, Grandy S. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract 2007; 61: 737-747.
10. DeClercq V, Taylor C, Zahradka P. Adipose tissue: the link between obesity and cardiovascular disease. Cardiovasc Hematol Disord Drug Targets 2008; 8: 228-237.
11. Imbeault P, Lemieux S, Prud'homme D et al. Relationship of visceral adipose tissue to metabolic risk factors for coronary heart disease: is there a contribution of subcutaneous fat cell hypertrophy? Metabolism 1999; 48: 355-362.
12. McElroy SL, Kotwal R, Malhotra S et al. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry 2004; 65: 634-651.
13. Wolf AM. What is the economic case for treating obesity? Obes Res 1998; 6(Suppl 1): 2S-7S.
14. Wang Y, Beydoun MA, Liang L, Caballero B, Kumanyika SK. Will all Americans become overweight or obese? estimating the progression and cost of the US obesity epidemic. Obesity (Silver Spring) 2008; 16: 2323-2330.
15. Jia H, Lubetkin EI. Obesity-related quality-adjusted life years lost in the U.S. from 1993 to 2008. Am J Prev Med 2010; 39: 220-227.
16. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff (Millwood) 2009; 28: w822-w831.
17. Runge CF. Economic consequences of the obese. Diabetes 2007; 56: 2668-2672.
18. Stafford RS, Farhat JH, Misra B, Schoenfeld DA. National patterns of physician activities related to obesity management. Arch Fam Med 2000; 9: 631-638.
19. Hill AJ. Does dieting make you fat? Br J Nutr 2004; 92(Suppl 1): S15-18.
20. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
21. Harwell TS, Vanderwood KK, Hall TO, Butcher MK, Helgerson SD. Factors associated with achieving a weight loss goal among participants in an adapted Diabetes Prevention Program. Prim Care Diabetes 2011; 5: 125-129.
22. Vanderwood KK, Hall TO, Harwell TS et al. Factors associated with the maintenance or achievement of the weight loss goal at follow-up among participants completing an adapted diabetes prevention program. Diabetes Res Clin Pract 2011; 91: 141-147.
23. Kramer MK, Kriska AM, Venditti EM et al. Translating the Diabetes Prevention Program: a comprehensive model for prevention training and program delivery. Am J Prev Med 2009; 37: 505-511.
24. Project Implicit: General Information. 2011. Available from URL:. Accessed 11 November 2011.
25. Teachman BA, Brownell KD. Implicit anti-fat bias among health professionals: is anyone immune? Int J Obes Relat Metab Disord 2001; 25: 1525-1531.
26. Foster GD, Wadden TA, Makris AP et al. Primary care physicians' attitudes about obesity and its treatment. Obes Res 2003; 11: 1168-1177.
27. Galuska DA, Will JC, Serdula MK, Ford ES. Are health care professionals advising obese patients to lose weight? JAMA 1999; 282: 1576-1578.
28. Abid A, Galuska D, Khan LK et al. Are healthcare professionals advising obese patients to lose weight? A trend analysis. MedGenMed 2005; 7: 10.
29. Ko JY, Brown DR, Galuska DA et al. Weight loss advice U.S. obese adults receive from health care professionals. Prev Med 2008; 47: 587-592.
30. Sciamanna CN, Tate DF, Lang W, Wing RR. Who reports receiving advice to lose weight? Results from a multistate survey. Arch Intern Med 2000; 160: 2334-2339.
31. Gade W, Gade J, Collins M, Schmit J, Schupp N. Failures of feedback: rush hour along the highway to obesity. Clin Lab Sci 2010; 23: 39-50.
32. Garber A. Hope and change for 2011. Endocrine Today 2011; 9: 1-3.
33. Wells JC. Thrift: a guide to thrifty genes, thrifty phenotypes and thrifty norms. Int J Obes (Lond) 2009; 33: 1331-1338.
34. Yu AP, Wu EQ, Birnbaum HG et al. Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. Curr Med Res Opin 2007; 23: 2157-2169.
35. Zimmett P. We should stop putting blame on obese people. Sydney Morning Herald, 19 January 2011.
36. Centers for Disease Control and Prevention. National Diabetes Fact Sheet, 2011. Available from URL:. Accessed 11 November 2011.
37. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004; 89: 463-478.
38. Heilbronn L, Smith SR, Ravussin E. Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. Int J Obes Relat Metab Disord 2004; 28(Suppl. 4): S12-21.
39. Jazet IM, Pijl H, Meinders AE. Adipose tissue as an endocrine organ: impact on insulin resistance. Neth J Med 2003; 61: 194-212.
40. Barbarroja N, Lopez-Pedrera R, Mayas MD et al. The obese healthy paradox: is inflammation the answer? Biochem J 2010; 430: 141-149.
41. Purkayastha S, Zhang G, Cai D. Uncoupling the mechanisms of obesity and hypertension by targeting hypothalamic IKK-beta and NF-kappaB. Nat Med 2011; 17: 883-887.
42. Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009; 297: 127-136.
43. Ross SA, Ekoe JM. Incretin agents in type 2 diabetes. Can Fam Physician 2010; 56: 639-648.
44. Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008; 34: 2-11.
45. Gauthier MS, Ruderman NB. Adipose tissue inflammation and insulin resistance: all obese humans are not created equal. Biochem J 2010; 430: e1-e4.
46. Vandanmagsar B, Youm YH, Ravussin A et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011; 17: 179-188.
47. Bluher M. The distinction of metabolically 'healthy' from 'unhealthy' obese individuals. Curr Opin Lipidol 2010; 21: 38-43.
48. Gregor MF, Hotamisligil GS. Inflammatory Mechanisms in Obesity. Annu Rev Immunol 2010; 29: 415-445.
49. Yki-Jarvinen H. Ectopic fat accumulation: an important cause of insulin resistance in humans. J R Soc Med 2002; 95(Suppl. 42): 39-45.
50. Centers for Disease Control and Prevention. National Diabetes Fact Sheet, 2007. Available from URL:. Accessed 11 November 2011.
51. AHRQ, Santaguida PL, Balion C et al. Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evid Rep Technol Assess (Summ) 2005; 128: 1-11.
52. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008; 31(Suppl. 1): S12-54.
53. World Health Organization/International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation, 2006.
54. Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol 2010; 55: 1310-1317.
55. Bays H, Abate N, Chandalia M. Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia. Future Cardiol 2005; 1: 39-59.
56. Lin JD, Wan HL, Li JC et al. Impaired glucose tolerance and impaired fasting glucose share similar underlying pathophysiologies. Tohoku J Exp Med 2007; 212: 349-357.
57. Wen CP, Cheng TY, Tsai SP, Hsu HL, Wang SL. Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan. Diabetes Care 2005; 28: 2756-2761.
58. Seshasai SR, Kaptoge S, Thompson A et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829-841.
59. Brunzell JD, Robertson RP, Lerner RL et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 1976; 42: 222-229.
60. Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007; 30: 8-13.
61. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007; 28: 187-218.
62. de Vegt F, Dekker JM, Jager A et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA 2001; 285: 2109-2113.
63. Hoerger TJ, Hicks KA, Sorensen SW et al. Cost-effectiveness of screening for pre-diabetes among overweight and obese U.S. adults. Diabetes Care 2007; 30: 2874-2879.
64. Sullivan SD, Ratner RE. Should the metabolic syndrome patient with prediabetes be offered pharmacotherapy? Curr Diab Rep 2010; 2: 91-98.
65. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 3066-3072.
66. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III), 2001. Available from URL:. Accessed 11 November 2011.
67. Lorenzo C, Wagenknecht LE, D'Agostino RB Jr et al Insulin resistance, beta-cell dysfunction, and conversion to type 2 diabetes in a multiethnic population: the Insulin Resistance Atherosclerosis Study. Diabetes Care 2010; 33: 67-72.
68. Wilson PW, D'Agostino RB, Fox CS, Sullivan LM, Meigs JB. Type 2 diabetes risk in persons with dysglycemia: the Framingham offspring study. Diabetes Res Clin Pract 2011; 92: 124-127.
69. Wilson PW, Meigs JB, Sullivan L et al. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham offspring Study. Arch Intern Med 2007; 167: 1068-1074.
70. Guerrero-Romero F, Rodriguez-Moran M, Gonzalez-Ortiz M, Martinez-Abundis E. Early decrease of the percent of HOMA beta-cell function is independently related to family history of diabetes in healthy young nonobese individuals. Diabetes Metab 2005; 31(4 Pt 1): 382-386.
71. Kolberg JA, Jorgensen T, Gerwien RW et al. Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort. Diabetes Care 2009; 32: 1207-1212.
72. Tethys Bioscience. Reimbursement: insurance coverage for the PreDx DRS, 2011. Available from URL:. Accessed 11 November 2011.
73. Heikes KE, Eddy DM, Arondekar B, Schlessinger L. Diabetes Risk Calculator: a simple tool for detecting undiagnosed diabetes and pre-diabetes. Diabetes Care 2008; 31: 1040-1045.
74. Kreider RB, Serra M, Beavers KM et al. A structured diet and exercise program promotes favorable changes in weight loss, body composition, and weight maintenance. J Am Diet Assoc 2011; 111: 828-843.
75. Nathan DM, Davidson MB, DeFronzo RA et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007; 30: 753-759.
76. Rhee MK, Herrick K, Ziemer DC et al. Many Americans have pre-diabetes and should be considered for metformin therapy. Diabetes Care 2010; 33: 49-54.
77. Food and Drug Administration. Questions and answers: orlistat and severe liver injury, 2010. Available from URL:. Accessed 11 November 2011.
78. Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for obesity: past, current, and future therapies. J Obes 2011; 2011: 179674.
79. Food and Drug Administration. Briefing document: lorcaserin hydrochloride (APD356), NDA 22-529, 2010.
80. Food and Drug Administration. Contrave advisory committee meeting briefing document, NDA 200063, 2010.
81. Food and Drug Administration. Qnexa advisory committee briefing document, 2010.
82. Lowry F. FDA panel flunks qnexa because of safety concerns, 2010. Available from URL:. Accessed 11 November 2011.
83. Arena Pharmaceuticals announces workforce reduction and provides lorcaserin regulatory update, 2011. Available from URL:. Accessed 11 November 2011.
84. FDA issues complete response to new drug application for contrave for the management of obesity, 2011. Available from URL:. Accessed 11 November 2011.
85. Vivus provides regulatory update on qnexa NDA, 2011. Available from URL:. Accessed 11 November 2011.
86. Bays HE. Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease. Expert Rev Cardiovasc Ther 2009; 7: 1429-1445.
87. Arena eyes obesity drug refiling by end of 2011. Available from URL:. Accessed 11 November 2011.
88. Desilets AR, Dhakal-Karki S, Dunican KC. Role of metformin for weight management in patients without type 2 diabetes. Ann Pharmacother 2008; 42: 817-826.
89. Gokcel A, Gumurdulu Y, Karakose H et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 2002; 4: 49-55.
90. Li CL, Pan CY, Lu JM et al. Effect of metformin on patients with impaired glucose tolerance. Diabet Med 1999; 16: 477-481.
91. Lily M, Godwin M. Treating prediabetes with metformin: systematic review and meta-analysis. Can Fam Physician 2009; 55: 363-369.
92. Ramachandran A, Snehalatha C, Mary S et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006; 49: 289-297.
93. Russell-Jones D. The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes. Int J Clin Pract 2010; 64: 1402-1414.
94. Gallwitz B. The evolving place of incretin-based therapies in type 2 diabetes. Pediatr Nephrol 2010; 25: 1207-1217.
95. Gilbert MP, Pratley RE. Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. Am J Med 2009; 122:(6 Suppl):S11-24.
96. Pinkney J, Fox T, Ranganath L. Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide. Ther Clin Risk Manag 2010; 6: 401-411.
97. Astrup A, Rossner S, Van Gaal L et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374: 1606-1616.
98. Garber A, Henry R, Ratner R et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-481.
99. Marre M, Shaw J, Brandle M et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268-278.
100. Zinman B, Gerich J, Buse JB et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009; 32: 1224-1230.
101. Henry R, Fonseca V, Tabanera y Palacios R, Brett J, Plutzky J. Liraglutide, a once-daily human GLP-1 analog, reduces systolic blood pressure with minimal impact from weight loss in subjects with type 2 diabetes. Endocrine Society 92nd Annual Meeting and Expo 2010. San Diego, CA.
102. The effect of liraglutide on body weight in obese subjects without diabetes. NCT00422058, 2011. Available from URL:. Accessed 11 November 2011.
103. Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with co-morbidities: SCALE™-obesity and pre-diabetes. NCT01272219, 2011. Available from URL:. Accessed 11 November 2011.
104. Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE™-diabetes. NCT01272232, 2011. Available from URL:. Accessed 11 November 2011.
105. Brownell KD, Kersh R, Ludwig DS et al. Personal responsibility and obesity: a constructive approach to a controversial issue. Health Aff (Millwood) 2010; 29: 379-387.
106. U.S. Department of Agriculture and U.S. Department of Health and Human Services. Dietary guidelines for Americans, 2010. Available from URL:. Accessed 11 November 2011.
107. Centers for Disease Control and Prevenetion. National Diabetes Prevention Program, 2011. Available from URL:. Accessed 11 November 2011.